Patient safety data
N = 8 patients . | Grades 1-2 . | Grade ≥3 . |
---|---|---|
Possible immune related | ||
Rash/immune system disorder | 4 | 3 |
Colitis | 0 | 1 |
Cough/pneumonitis | 4 | 0 |
LFT elevation | 5 | 0 |
Cytopenias | ||
Anemia | 4 | 4 |
Thrombocytopenia | 0 | 2 |
Neutropenia | 0 | 1 |
Other | ||
Chills | 2 | 0 |
Constipation/abdominal pain | 4 | 0 |
Fatigue | 5 | 1 |
Infection∗ | 4 | 9 |
Injection site reaction | 3 | 0 |
GI bleeding | 2 | 0 |
Mucositis | 3 | 1 |
Myalgia | 3 | 1 |
N = 8 patients . | Grades 1-2 . | Grade ≥3 . |
---|---|---|
Possible immune related | ||
Rash/immune system disorder | 4 | 3 |
Colitis | 0 | 1 |
Cough/pneumonitis | 4 | 0 |
LFT elevation | 5 | 0 |
Cytopenias | ||
Anemia | 4 | 4 |
Thrombocytopenia | 0 | 2 |
Neutropenia | 0 | 1 |
Other | ||
Chills | 2 | 0 |
Constipation/abdominal pain | 4 | 0 |
Fatigue | 5 | 1 |
Infection∗ | 4 | 9 |
Injection site reaction | 3 | 0 |
GI bleeding | 2 | 0 |
Mucositis | 3 | 1 |
Myalgia | 3 | 1 |
Grading for adverse events was recorded throughout the study and assigned by the investigators according to the Common Terminology Criteria for Adverse Events version 4.0.
GI, gastrointestinal; LFT, -liver function test.
Some patients enrolled in study had multiple adverse events due to infection.